Quantcast

Latest Daunorubicin Stories

2010-10-26 07:00:00

PRINCETON, N.J., Oct. 26 /PRNewswire/ -- Celator Pharmaceuticals today announced that it has completed enrollment in a phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus intensive salvage therapy in adult patients with acute myeloid leukemia (AML) in first relapse. The study, which is supported through a partnership with The Leukemia & Lymphoma Society® (LLS), achieved its target enrollment of 120...

2010-09-01 07:00:00

PRINCETON, N.J., Sept. 1 /PRNewswire/ -- Celator Pharmaceuticals, a privately held pharmaceutical company developing new and more effective therapies to treat cancer based on the company's proprietary technology, today announced that it raised $20 million in a Series D private equity financing. Proceeds will support completion of ongoing clinical trials and activities related to advancing the company's lead investigational product, CPX-351 (Cytarabine:Daunorubicin) Liposome Injection as a...

2010-06-21 12:38:00

PRINCETON, N.J., June 21 /PRNewswire/ -- Celator Pharmaceuticals today announced that it has expanded its research agreement with Cephalon, Inc. (Nasdaq: CEPH). The research agreement provides for the utilization of Celator's proprietary technology in an ongoing drug development and life-cycle management program at Cephalon. "We are pleased that work with this research program has led to its expansion and excited that a global biopharmaceutical company of Cephalon's stature is...

2010-06-14 07:00:00

PRINCETON, N.J., June 14 /PRNewswire/ -- Celator Pharmaceuticals today announced that new data from a preclinical leukemia study in mice demonstrate that its lead product, CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, alone or in combination with clofarabine or azacytidine can improve treatment outcomes compared to the combination of either agent with the conventional (unencapsulated) cytarabine:daunorubicin regimen. The results were presented at the 15th Congress of the European...

2010-06-07 07:00:00

PRINCETON, N.J., June 7 /PRNewswire/ -- Celator Pharmaceuticals today announced that a subset analysis of data from its Phase 2 study in newly diagnosed acute myeloid leukemia (AML) demonstrates that CPX-351 (Cytarabine:Daunorubicin) Liposome Injection can induce complete remissions in patients following the failure of induction therapy with conventional cytarabine and daunorubicin (the "7+3" regimen). The results were presented at the 2010 American Society of Clinical Oncology (ASCO)...

2010-05-03 07:00:00

PRINCETON, N.J., May 3 /PRNewswire/ -- Celator Pharmaceuticals, Inc. today announced positive results from its Phase 2 study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin (the "7+3" regimen) in patients, 60-75 years of age, with untreated acute myeloid leukemia (AML). The primary endpoint of the study, the rate of patients achieving a complete remission with CPX-351 compared to "7+3," achieved statistical significance. In addition,...

2010-04-22 07:00:00

PRINCETON, N.J., April 22 /PRNewswire/ -- Celator Pharmaceuticals today announced data from animal studies demonstrating the superior bone marrow uptake of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, its lead clinical-stage program, as well as the enhanced circulation kinetics and efficacy of its preclinical hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation were presented at the 101st Annual Meeting of the American Association for Cancer Research in Washington, DC...

2010-04-12 07:00:00

PRINCETON, N.J., April 12 /PRNewswire/ -- Celator Pharmaceuticals today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent covering the company's CombiPlex® technology platform (U.S. patent application 10/417,631), the basis for the company's product pipeline which includes two clinical-stage products for acute myeloid leukemia and colorectal cancer. CombiPlex is a unique approach in the development of combination...

2009-12-14 10:54:00

ROCKAWAY, N.J., Dec. 14 /PRNewswire/ -- The third edition of Infusion Nursing: An Evidence-Based Approach, published by the Infusion Nurses Society (INS), includes Totect(®), the only FDA-approved treatment for anthracycline extravasation.(1) Anthracyclines are a group of chemotherapy medications including daunorubicin, doxorubicin, idarubicin and epirubicin that have been used in the treatment of various types of cancer since the early 1970s.(2) According to the INS...

2009-12-08 15:26:45

A targeted drug that is active against acute myeloid leukemia (AML) is particularly effective when teamed with chemotherapy in patients whose cancer cells harbor a key genetic mutation, researchers at Dana-Farber Cancer Institute and their colleagues will report at the American Society of Hematology's (ASH) annual meeting on Monday, Dec. 7 (Ernest N. Morial Convention Center, Room 343-345, 5:15 pm CT). The Phase I study focused on the potential of administering the drug midostaurin (PK412)...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related